USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A(165b) alternative splicing via regulating SRSF1 and SRPK1

BACKGROUND: The benefit of targeted therapy for renal cell carcinoma (RCC) is largely crippled by drug resistance. Rapid disease progression and poor prognosis occur in patients with drug resistance. New treatments demand prompt exploration for clinical therapies. Ubiquitin-specific peptidase 39 (US...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Xiu-wu, Xu, Da, Chen, Wen-jin, Chen, Jia-xin, Chen, Wei-jie, Ye, Jian-qing, Gan, Si-shun, Zhou, Wang, Song, Xu, Shi, Lei, Cui, Xin-gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454004/
https://www.ncbi.nlm.nih.gov/pubmed/34544400
http://dx.doi.org/10.1186/s12935-021-02161-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454004/
https://www.ncbi.nlm.nih.gov/pubmed/34544400
http://dx.doi.org/10.1186/s12935-021-02161-x

Ejemplares similares